Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arginine deiminase is an enzyme that catalyzes the irreversible hydrolysis of L-arginine to citrulline and ammonia, representing the first step in the anaerobic degradation of arginine[4][6]. It is not present in high eukaryotes but is found in certain bacteria such as Pseudomonas aeruginosa[4][6]. Arginine deiminase has been investigated as a potential antimicrobial and antiparasitic drug target due to its absence in humans and essential role in microbial metabolism[4]. In oncology, pegylated forms of this enzyme (pegylated arginine deiminase) are being studied for their ability to deprive tumor cells of extracellular arginine, which some cancers require for growth[1][3]. The mechanism involves enzymatic depletion of systemic L-arginine, leading to inhibition of tumor cell proliferation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on arginine deiminase.